Health

Abridge lost AI scribing to Microsoft and Epic; its next market has a $100 million price from Wolters Kluwer

Microsoft and Epic took two of every three new AI-scribe dollars this year, and Abridge, which built that market, is selling what comes after the note. The decision-support category it is moving into just got a public price, Wolters Kluwer's $100 million AgileMD deal, and that price is what Abridge's $6.69 billion private mark has to outrun.

Richard TangRichard Tangthree-minute read
Share
Shiv Rao, co-founder and chief executive of Abridge, arms crossed, in a dark zip jacket against a warm-lit wall
Shiv Rao, co-founder and chief executive of Abridge, which this week pushed its clinical Assistant past the note at HLTH in Las Vegas.

Abridge$6.69B — Abridge, private, latest valuation $6.69B created the market for AI medical scribes, and this year that market stopped being winnable: Microsoft−1.73% — Microsoft, down 1.73 percent today and Epic now capture about two of every three new scribe dollars 12. Abridge's answer, announced at the HLTH conference in Las Vegas this week, is to sell what comes after the note; its clinical Assistant answered more than 40,000 questions from Department of Veterans Affairs clinicians last month 3.

The catch is the door it is running through. On November 13 the category it is escaping into got a public price, Wolters Kluwer's+0.77% — Wolters Kluwer, up 0.77 percent today $100 million deal for a 23-person decision-support firm, and that is the number Abridge's $6.69 billion private valuation has to outrun 45.

The note became a feature of the record

Healthcare AI spending doubled to $3.7 billion this year, still the largest vertical market for AI 2. Scribing grew far more slowly, because every major electronic health record now ships its own scribe, Microsoft's Dragon Copilot and Epic's Art among them, and the AI-native vendors that pioneered the category lost share 26. A note is a byproduct of the record, so the record's owner wins on distribution; Menlo Ventures, which surveyed 550 healthcare and life-sciences executives, calls pure note-taking largely commoditized 7.

Clinical copilots grew 5.5x in 2026 while ambient scribing grew 1.6x

The money is moving to what follows the note, not the note

0x2x4x6xClinical copilots5.5xAbridge's new marketPatient engagement, front office4.5xAll healthcare AI2.5xAmbient scribing1.6x
Data
Value
Clinical copilots5.5x
Patient engagement, front office4.5x
All healthcare AI2.5x
Ambient scribing1.6x
Year-over-year growth multiples in US healthcare AI spending by category, 2026, from Menlo Ventures' 2026 State of AI in Healthcare, a survey of 550 US healthcare and life-sciences executives.2,6

The Assistant sells the answer, not the note

What is new this week is scale in the layer above documentation. The Assistant reads the chart, runs the risk scores, drafts the handoff and answers clinical questions with citations, on infrastructure more than 300 health systems have already security-cleared 89. Its new Local Pathways feature surfaces each health system's own care guidance, today buried in PDFs and intranets, beside the patient in front of the clinician 8, and Wiley will license nearly 10,000 Cochrane systematic reviews into those answers 10.

Meeting every clinical guideline would take a primary care clinician a 27-hour workday, one 2022 estimate found 3; the product bet is that the searching collapses into a question asked in place. Through the National Association of Community Health Centers, the Assistant also goes free to clinicians serving some 52 million people, many in rural areas, the deliberate counter to a divide this technology otherwise widens 3.

The escape route is where the money already is

Wolters Kluwer, the Dutch publisher whose UpToDate reference tool is standard in US hospitals, agreed on November 13 to pay up to $100 million for AgileMD, a 23-person firm expected to book $7 million of annual revenue this year 4. Its own copilot, UpToDate Expert AI, is already in more than 2,700 US hospitals 4. An incumbent can buy into this category outright; Abridge has to earn it system by system, against OpenEvidence~$6B — OpenEvidence, private, latest valuation ~$6B, the clinical copilot providers already choose most 1.

Below it, OpenAI$1.18T — OpenAI, private, latest valuation $1.18T runs a prior-authorization task for 8.5 cents, as we wrote on November 17 5. Abridge is building computer-use agents, which drive other software the way a person does, for applications with no API, alongside a Menlo-reported Availity deal for real-time prior authorization 111; at CVS, one such agent cleared a months-long document backlog over a weekend 11.

The clinician's question is what is left to own

The chain is short to state: models made the note cheap, the EHR bundled it, and what stays defensible is the trusted answer at the moment of care, wired to the chart, the published evidence and the system's own guidance. Abridge holds more of that wiring than anyone, and the VA numbers say clinicians already use it.

The note was always going to ship free with the record; the question in front of the patient was not. For listed readers, the first pricing arrives at Wolters Kluwer, where the deal closes by early 2027 and must earn back its cost of capital within five years 4.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading MSFT

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year

    A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.

    Health

    GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

    About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

    Health

    CMS's CRUSH rule reaches past Medicare into Molina's $42 billion Medicaid book

    The November 18 rout priced the proposal as a UnitedHealth-Humana Medicare bill. Molina is leaving that business, so for it the rule's weight falls on the Medicaid audit duties covering the $42 billion premium book that carries its $9.50 2027 earnings framework.

    Health

    AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

    A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

    Health

    OpenEvidence CEO tells medical students to take paper exams as OpenAI and Anthropic give doctors AI free

    Daniel Nadler built a $15 billion company on giving doctors AI answers free. On Monday he warned the doctors still training on his tool that AI erodes the skill that makes an answer worth having.

    Health

    Molina Healthcare jumps 8% on a CMS work-rule delay; director Steven Orlando sold 702 shares at $227.33

    A CMS work-rule delay bought Molina's Medicaid book time, not margin, and insiders including director Steven Orlando sold into the strength. New buyers are paying roughly 24 times a 2027 framework that is not yet guidance and must still be earned in February.

    Subscribe to TheInference for free